IonQ's 2027 Revenue Math Meets a Market That Won't Wait

IonQ closed at EUR 38.32, 48% below its 52-week high, as Mizuho and BofA back the quantum story while revenue waits until 2027.

Quantum computing has long been sold as the next frontier of technology, a realm where qubits unlock problems that classical machines can only stare at in frustration. IonQ sits squarely at the center of that promise — and squarely in the uncomfortable gap between laboratory breakthroughs and the revenue lines investors actually care about.

That tension was on full display Monday, when the stock slipped 0.8% to close at EUR 38.32 even as the broader market moved higher. With no company-specific bad news to point to, observers attributed the pullback to profit-taking and the stock's persistently wide trading range. The shares remain 48% below their 52-week high, a discount that says plenty about how much skepticism still surrounds the young sector's high-growth pioneers.

Wall Street Sees the Story, Just Not Yet the Earnings

Mizuho Securities offered a counterweight the same day, reaffirming its "Outperform" rating with a $52.00 price target after meetings with IonQ's CFO and COO. The analysts acknowledged prior target cuts tied to valuation concerns following the company's analyst day, but left the quantum growth narrative intact. Their confidence leans heavily on 2027, when the ramp-up of Superion 256 systems is expected to take hold.

Bank of America Securities had already planted its flag a few days earlier, initiating coverage on September 28 with a Buy rating and a $60.00 target. The bank pointed to semiconductor-based scaling and IonQ's broad positioning across quantum computing, communication, and sensing as the pillars of its thesis.

Big Contracts, Long Runways

The order book looks impressive on paper. Mizuho estimates Superion 256 systems could sell for $25 million to $30 million apiece — meaningful sums that could reshape the company's financial base. The catch is timing. IonQ announced a contract with Florida International University on September 24 to deliver a Superion 256, but campus installation isn't slated until late 2027. A separate, higher-profile project near Nvidia — announced roughly two weeks ago — follows the same 2027 timeline, though the stock has gained 2.5% since that disclosure.

Investors, in other words, are being asked to bridge a multi-year gap between signed agreements and recognized revenue.

Where the Technology Actually Stands

The scientific progress is harder to dismiss. On September 22, IonQ's team demonstrated a real-time quantum error-correction decoder running on a standard commercial processor. Benchmark circuits simulated up to 408 logical qubits and more than 31.5 million operations with minimal stretching time — a direct strike at one of the biggest bottlenecks on the road to fault-tolerant computing.

Two days later, the company reported a generative quantum model for radar applications that outperformed two classical comparison methods. In one test case, the system posted a filtered F1 score of 0.41 against classical baselines of 0.24 and 0.16. The study also exposed a limitation: when raw data were preprocessed to approximate a Gaussian distribution, the quantum advantage largely evaporated.

IonQ has kept its commercial outreach running alongside the research. On October 1, it launched the CQ Connect webinar series with EPB, aimed at showing executives how to apply quantum and networking technology in practice.

The Patience Premium

Technically, the stock is holding a modest line. At EUR 38.32, it trades just above its 200-day moving average of EUR 37.70 — a thin cushion given the 48% gap to its 52-week high.

The setup captures IonQ's core dilemma: ambitious plans that demand years of investor faith before the numbers arrive. Buying this stock isn't buying an established business — it's a wager on flawless scaling through 2027. Any delay along that path would likely hit the shares hard. The technological case is real, and the partnerships with heavyweights and research institutions keep IonQ visible and validated. But until commercial viability catches up with the vision, valuation anxiety will set the tempo.